首页 > 产品中心 > 抗体 > 药物对照抗体

Anti-Human PCSK9 Reference Antibody (Bococizumab, RUO) (HV275046)

价格:
规格:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
  • 概述

  • 图片

  • 参考文献

  • 产品说明书

概述
货号HV275046
品牌abinScience
描述
Bococizumab (HV275046) is a research-grade recombinant antibody targeting Proprotein convertase subtilisin/kexin type 9. Produced in mammalian cells with native-like glycosylation.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
  • Native Glycosylation — Mammalian expression ensures native-like patterns.
种属反应性Human
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
同种型IgG2-kappa
表达系统Mammalian cells
靶标Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
内毒素水平< 10 EU/mg
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
Accession号Q8NBP7
状态Liquid
保存溶液 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

稳定性和存储Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名PF-04950615, RN-316, 1407495-02-6
背景

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha).

1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658
2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796
3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702
4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458
5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827
6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
NoteFor research use only. Not suitable for clinical or therapeutic use.
Isotype ControlHuman IgG2 Recombinant Isotype Control Antibody (HyHEL-10) (HV988107)
图片
  • SDS-PAGE

    SDS-PAGE for Research Grade Bococizumab

  • Bioactivity

    SEC-HPLC detection for Research Grade Bococizumab.

  • Bioactivity

    Detects Human PCSK9 in indirect ELISAs.
    Immobilized Human PCSK9, His Tag (Catalog No: HV275011) at 1 μg/mL (100 μL/well) on an Anti-His antibody (Catalog No: YP205015) Coated plate can bind Human PCSK9 Mab

参考文献
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量,自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项,自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐